ArticleCurrent opinion in nephrology and hypertension2020
Pain management in patients with chronic kidney disease and end-stage kidney disease.
Article in Current opinion in nephrology and hypertension, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07421674 (Application Research of Hydromorphinone Sustained-release Tablets in the Treatment of Elderly Patients With Cancer Pain Accompanied by Renal Insufficiency), which is not on this map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Application Research of Hydromorphinone Sustained-release Tablets in the Treatment of Elderly Patients With Cancer Pain Accompanied by Renal Insufficiency
Who cites it
40 citing papers in PubMed, 79 citations in OpenAlex.
- Chronic Pain Locations, Characteristics, and Associations With Other Symptoms in Adults Receiving Maintenance Hemodialysis: Findings From the HOPE Consortium Trial.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2026Trial
- Adapting a pain coping skills training intervention for people with chronic pain receiving maintenance hemodialysis for end stage Kidney disease.Journal of behavioral medicine · 2025Trial
- Pain Coping Skills Training for Patients Receiving Hemodialysis: The HOPE Consortium Randomized Clinical Trial.JAMA internal medicine · 2025Trial
- Palliative Care Interventions for Patients With Kidney Disease: A Scoping Review by the Kidney Disease Aging Research Collaborative.Journal of the American Geriatrics Society · 2026Article
- Can Chronic Pain Accelerate Chronic Kidney Disease? Is Pain a Disease Modifier Rather than a Symptom?Life (Basel, Switzerland) · 2026Article
- Psoriasis and chronic kidney disease: a systemic inflammatory link and a practical kidney assessment pathway.Clinical kidney journal · 2026Article
- A qualitative study examining barriers to buprenorphine for pain management in patients with end stage kidney disease undergoing hemodialysis.The journal of pain · 2026Article
- Lifetime Cannabis Use Is Associated With Brain Volume and Cognitive Function in Middle-Aged and Older Adults.Journal of studies on alcohol and drugs · 2026Article
- Deciding between conservative kidney management and dialysis in older people with kidney failure: a narrative review.Clinical kidney journal · 2026Review
- Drug-induced methemoglobinemia in a child with comorbidity and polypragmasia: Case report.The International journal of risk & safety in medicine · 2026Article
- Perioperative management with close renal function monitoring in a dental patient receiving SGLT2 inhibitor therapy for non-diabetic chronic kidney disease.Journal of dental anesthesia and pain medicine · 2026Article
- Probable neuropsychiatric toxicity induced by dihydrocodeine in a peritoneal dialysis patient: a case report and literature review.BMC nephrology · 2026Review
- International variations in chronic kidney disease patients' pain experience and its management.Clinical kidney journal · 2026Article
- Neuropathic Pain, Polyneuropathy, and Quality of Life in Patients Receiving Dialysis.Medical science monitor : international medical journal of experimental and clinical research · 2025Observational
- The Present and Future of Pain Management in Patients With Chronic Kidney Disease: A Narrative Review.Cureus · 2025Review
- All-Cause Mortality and Bleeding Risks Associated With Serotonin Reuptake Inhibitors in Patients With End-Stage Kidney Disease and Depression: A Nationwide Cohort Study.Psychiatry investigation · 2025Article
- Preventing chronic kidney disease and maintaining kidney health: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.Kidney international · 2025Article
- Dialysis Disequilibrium Syndrome as a Cause of Unexplained Pain in a Young Female: A Case Report.Cureus · 2025Article
- Exploring health challenges and coping strategies in young patients undergoing maintenance hemodialysis: a qualitative study.BMC nephrology · 2025Article
- Management of Painful Post-Traumatic Trigeminal Neuropathy With Topical Anesthesia Combined With a Psychological Approach: A Case Report.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewThis review evaluates current recommendations for pain management in chronic kidney disease (CKD) and end-stage kidney disease (ESKD) with a specific focus on evidence for opioid analgesia, including the partial agonist, buprenorphine. RECENT
findingsRecent evidence supports the use of physical activity and other nonpharmacologic therapies, either alone or with pharmacological therapies, for pain management. Nonopioid analgesics, including acetaminophen, topical analgesics, gabapentinoids, serotonin-norepinephrine reuptake inhibitors, and TCA may be considered based on pain cause and type, with careful dose considerations in kidney disease. NSAIDs may be used in CKD and ESKD for short durations with careful monitoring. Opioid use should be minimized and reserved for patients who have failed other therapies. Opioids have been associated with increased adverse events in this population, and thus should be used cautiously after risk/benefit discussion with the patient. Opioids that are safer to use in kidney disease include oxycodone, hydromorphone, fentanyl, methadone, and buprenorphine. Buprenorphine appears to be a promising and safer option due to its partial agonism at the mu opioid receptor. SUMMARY: Pain is poorly managed in patients with kidney disease. Nonpharmacological and nonopioid analgesics should be first-line approaches for pain management. Opioid use should be minimized with careful monitoring and dose adjustment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.